RethinkX | 2 June 2026
For weight loss, the current evidence is that this generation of GLP-1 drugs do need to be continued to maintain their effects. When users stop taking semaglutide or tirzepatide, a substantial proportion of the weight lost tends to return fairly quickly. This reflects the underlying biology of the drug. Obesity has a strong biological set-point, driven by hormonal and neurological mechanisms that push the body back toward a higher weight after weight loss. GLP-1 drugs don't actually cure this, they manage it in the same way that blood pressure medications manage hypertension without curing the underlying susceptibility.
This does not mean that indefinite daily or weekly high-dose therapy is the only option. Several alternative patterns are under investigation, including low-dose maintenance (periodic or ongoing, at doses lower than those used for active weight loss); intermittent cycling; and the possibility that long-term metabolic changes from extended use may allow some users to maintain results with less frequent dosing. The field has not yet established which of these patterns will prove most effective and most widely preferred.
For the muscle-gain drugs (myostatin/activin blockers), the picture is similar in that muscle gained under the influence of these drugs would tend to decline after cessation, particularly in older adults who face ongoing sarcopenic pressure from aging. Periodic or maintenance use is likely to be the most effective strategy for long-term benefit.
Asking "do I have to take this forever?" applies the logic of acute treatment (take the drug until the problem is fixed, then stop) to a chronic management situation. Most people with hypertension, high cholesterol, or hypothyroidism take their medications indefinitely, not because their condition is untreatable but because the biology requires ongoing management. There is no moral or practical objection to this, it is simply managing a biological reality.
The closer analogy may be vitamins and supplements. Many adults take vitamin D, fish oil, or magnesium indefinitely because they benefit from ongoing supplementation that their diet and lifestyle don't naturally provide. As HOTs become lower-cost, safer, and better characterized, a shift to a model of HOTs as a routine part of a health maintenance regimen, similar to vitamins is plausible.
For older adults, the question of indefinite use has a particularly clear answer. Sarcopenia and obesity together form a self-reinforcing trap that, once broken by HOTs, requires ongoing management to prevent regression. The combination of fat loss and muscle gain from next-generation HOTs is for many older adults is a permanent enabling condition for functional independence, mobility, and quality of life.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.
